NPM1 and acute myeloid leukemia: To explore whether the risk signature is an independent prognostic factor in AML, we carried out a stratification analysis to assess the efficiency of the signature in various subgroups with different clinical variables, including age, gender, chromosomal abnormality or not, FLT3, IDH1, NPM1 and RAS mutation status (Supplemental Table 1).